Genetische Risiken und Therapieentwicklung bei Netzhautdegenerationen

Translated title of the contribution: Genetic risks and therapy development in retinal degeneration

Felix Grassmann*, Bernhard Weber

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Understanding the genetic causes of monogenic and complex retinal degenerations is crucial in elucidating the basic physiological processes involved in the development of the respective disease. Building upon such an insight will enable the development of therapies precisely tailored to patients. This review summarizes the present state of knowledge on the genetics of hereditary retinal dystrophies and complex retinal degeneration, implicating a number of causal mechanisms and molecular pathological conditions underlying the clinically and genetically heterogeneous symptoms of retinal degeneration. Building on this knowledge, the role of genetics in devising treatment strategies becomes obvious and is revealed by a plethora of therapeutic treatments in this field. Some of these will be explored in more depth, with selected examples, in other articles included in this special issue of Medizinische Genetik.

Translated title of the contributionGenetic risks and therapy development in retinal degeneration
Original languageGerman
Pages (from-to)195-201
Number of pages7
JournalMedizinische Genetik
Issue number2
Early online date29 Jun 2017
Publication statusPublished - 2017


  • Complex retinal degeneration
  • Genetic risk factors
  • Genetics
  • Hereditary retinal dystrophy
  • Therapy development


Dive into the research topics of 'Genetic risks and therapy development in retinal degeneration'. Together they form a unique fingerprint.

Cite this